PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34046681-6 2021 In addition to BTK, ibrutinib also inhibits IL2 inducible T cell Kinase (ITK). ibrutinib 20-29 IL2 inducible T cell kinase Homo sapiens 44-71 34046681-6 2021 In addition to BTK, ibrutinib also inhibits IL2 inducible T cell Kinase (ITK). ibrutinib 20-29 IL2 inducible T cell kinase Homo sapiens 73-76 31861854-4 2019 Ibrutinib, the first-in-class BTKi, also inhibits Tec family kinases such as interleukin-2-inducible kinase (ITK), a proximal member of the T-cell receptor signaling cascade. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 77-107 34000704-2 2021 Although ibrutinib exhibited excellent antitumor activity, it was associated with certain adverse reactions, with off-target effects against EGFR, Itk and Src family kinases. ibrutinib 9-18 IL2 inducible T cell kinase Homo sapiens 147-150 33981831-3 2021 However, the off-target inhibition of ibrutinib on interleukin-2 (IL-2)-inducible T cell kinase (ITK) may reduce rituximab"s antibody-dependent cellular cytotoxicity (ADCC) efficacy. ibrutinib 38-47 IL2 inducible T cell kinase Homo sapiens 66-95 33981831-3 2021 However, the off-target inhibition of ibrutinib on interleukin-2 (IL-2)-inducible T cell kinase (ITK) may reduce rituximab"s antibody-dependent cellular cytotoxicity (ADCC) efficacy. ibrutinib 38-47 IL2 inducible T cell kinase Homo sapiens 97-100 32683672-8 2021 Besides BTK, ibrutinib additionally inhibits interleukin-2-inducible T cell kinase (ITK) which is involved in T cell differentiation. ibrutinib 13-22 IL2 inducible T cell kinase Homo sapiens 45-82 32683672-8 2021 Besides BTK, ibrutinib additionally inhibits interleukin-2-inducible T cell kinase (ITK) which is involved in T cell differentiation. ibrutinib 13-22 IL2 inducible T cell kinase Homo sapiens 84-87 32683672-14 2021 In summary, BTK/ITK inhibition with ibrutinib during CART cell culture can improve yield and function of CLL patient-derived CART cell products. ibrutinib 36-45 IL2 inducible T cell kinase Homo sapiens 16-19 32640487-4 2021 Here, we summarize the current knowledge of BTK/IL-2-inducible T-cell kinase (ITK) signaling in immunopathology and lymphopenia and discuss the potential of BTK/ITK dual inhibitors such as ibrutinib in modulating immunopathology and lymphopenia, for COVID-19 therapy. ibrutinib 189-198 IL2 inducible T cell kinase Homo sapiens 161-164 32306816-1 2020 Ibrutinib is a BTK/ITK inhibitor with efficacy for the treatment of various lymphoid cancers, including CLL. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 19-22 33043320-1 2020 Ibrutinib, a known Burton"s tyrosine kinase (BTK) and interleukin-2 inducible T-cell kinase (ITK) inhibitor, is used for the treatment of B-cell disorders (chronic lymphocytic leukemia [CLL] and various other lymphomas) and chronic graft versus host disease following allogeneic hematopoietic cell transplantation. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 54-91 33043320-1 2020 Ibrutinib, a known Burton"s tyrosine kinase (BTK) and interleukin-2 inducible T-cell kinase (ITK) inhibitor, is used for the treatment of B-cell disorders (chronic lymphocytic leukemia [CLL] and various other lymphomas) and chronic graft versus host disease following allogeneic hematopoietic cell transplantation. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 93-96 33593794-8 2021 We investigated the impact of modulating ITK signaling with ibrutinib, an FDA-approved tyrosine kinase inhibitor, and found that anti-OX40/anti-CTLA-4/ibrutinib therapy further enhanced CD8+ T cell-specific Eomes expression, leading to enhanced tumor regression and improved survival, both of which were associated with increased T-cell effector function across multiple tumor models. ibrutinib 60-69 IL2 inducible T cell kinase Homo sapiens 41-44 33593794-8 2021 We investigated the impact of modulating ITK signaling with ibrutinib, an FDA-approved tyrosine kinase inhibitor, and found that anti-OX40/anti-CTLA-4/ibrutinib therapy further enhanced CD8+ T cell-specific Eomes expression, leading to enhanced tumor regression and improved survival, both of which were associated with increased T-cell effector function across multiple tumor models. ibrutinib 151-160 IL2 inducible T cell kinase Homo sapiens 41-44 31869418-3 2019 The bleeding associated with ibrutinib use is thought to be due to a combination of on-target irreversible Btk inhibition, as well as off-target inhibition of other kinases, including EGFR, ITK, JAK3, and Tec kinase. ibrutinib 29-38 IL2 inducible T cell kinase Homo sapiens 190-193 31861854-4 2019 Ibrutinib, the first-in-class BTKi, also inhibits Tec family kinases such as interleukin-2-inducible kinase (ITK), a proximal member of the T-cell receptor signaling cascade. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 109-112 28714866-1 2017 BACKGROUND: Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton"s tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). ibrutinib 12-21 IL2 inducible T cell kinase Homo sapiens 119-147 31511358-10 2019 In contrast to tirabrutinib, ibrutinib had inhibitory effects on T cell activation, probably because of ITK inhibition. ibrutinib 29-38 IL2 inducible T cell kinase Homo sapiens 104-107 31025232-13 2019 An irreversible inhibitor of ITK, ibrutinib, blocked ex vivo Th17 generation and IL-17A production, conversely augmented FOXP3 expression only at low doses in Treg cultures. ibrutinib 34-43 IL2 inducible T cell kinase Homo sapiens 29-32 31013298-7 2019 A preclinical study of ibrutinib, a small molecule inhibitor of mouse and human ITK, in established lymphoma was carried out and showed lymphoma regression in 8/12 (67%) mice. ibrutinib 23-32 IL2 inducible T cell kinase Homo sapiens 80-83 30742126-6 2019 By examining cell signaling on this map, we rationally selected ibrutinib, a BTK and ITK inhibitor, and administered it before T cell activation to direct differentiation toward a T stem cell memory (TSCM)-like phenotype. ibrutinib 64-73 IL2 inducible T cell kinase Homo sapiens 85-88 29285806-1 2018 OBJECTIVE: Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK) in B lymphocytes as well as other kinases including interleukin-2-inducible T-cell kinase (ITK) in CD4+ Th2 regulatory T cells. ibrutinib 11-20 IL2 inducible T cell kinase Homo sapiens 173-176 28924018-3 2017 Ibrutinib inhibits Bruton tyrosine kinase in B cells and interleukin-2-inducible T-cell kinase in T cells. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 57-94 29669753-1 2018 Ibrutinib has previously been shown to inhibit Bruton"s tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 82-119 29669753-1 2018 Ibrutinib has previously been shown to inhibit Bruton"s tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 121-124 29669753-3 2018 Whether ibrutinib inhibition of ITK can lead to clinical response in T-cell malignancies is unknown. ibrutinib 8-17 IL2 inducible T cell kinase Homo sapiens 32-35 29669753-4 2018 We hypothesized that ibrutinib-mediated ITK inhibition in T-cell lymphoma would result in decreased signaling through the T-cell receptor pathway and promote antitumor immune response by driving selective cytotoxic Th1 CD4 effector T-cell differentiation. ibrutinib 21-30 IL2 inducible T cell kinase Homo sapiens 40-43 29669753-11 2018 Our data suggest that ibrutinib inhibition of ITK has limited clinical activity in T-cell lymphoma. ibrutinib 22-31 IL2 inducible T cell kinase Homo sapiens 46-49 28714866-1 2017 BACKGROUND: Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton"s tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). ibrutinib 12-21 IL2 inducible T cell kinase Homo sapiens 149-152 27590878-3 2016 Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 42-45 27802969-1 2016 Ibrutinib, a potent and irreversible small-molecule inhibitor of both Bruton"s tyrosine kinase and interleukin-2 inducible kinase (ITK), has been used to treat relapsed/refractory chronic lymphocytic leukemia (CLL) with prolongation of progression-free and overall survival. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 99-129 27802969-1 2016 Ibrutinib, a potent and irreversible small-molecule inhibitor of both Bruton"s tyrosine kinase and interleukin-2 inducible kinase (ITK), has been used to treat relapsed/refractory chronic lymphocytic leukemia (CLL) with prolongation of progression-free and overall survival. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 131-134 27802969-8 2016 We postulate that ibrutinib augments the graft-versus-leukemia (GVL) benefit through a T-cell-mediated effect, most likely due to ITK inhibition. ibrutinib 18-27 IL2 inducible T cell kinase Homo sapiens 130-133 27678331-9 2016 The dual activity toward TEC family (BTK and ITK) and ERBB family kinases was unique to ibrutinib, as ERBB inhibitors do not inhibit or covalently bind BTK or ITK. ibrutinib 88-97 IL2 inducible T cell kinase Homo sapiens 45-48 26942065-1 2016 Ibrutinib (PCI-32765) is an irreversible dual Btk/Itk inhibitor shown to be effective in treating several B cell malignancies. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 50-53 34508613-5 2021 BGB-3111 provides better safety than another BTK inhibitor, ibrutinib as ibrutinib inhibits the inducible T-cell kinase (ITK) as an off-target effect but BGB-3111 does not inhibit ITK. ibrutinib 60-69 IL2 inducible T cell kinase Homo sapiens 96-119 34508613-5 2021 BGB-3111 provides better safety than another BTK inhibitor, ibrutinib as ibrutinib inhibits the inducible T-cell kinase (ITK) as an off-target effect but BGB-3111 does not inhibit ITK. ibrutinib 60-69 IL2 inducible T cell kinase Homo sapiens 121-124 34508613-5 2021 BGB-3111 provides better safety than another BTK inhibitor, ibrutinib as ibrutinib inhibits the inducible T-cell kinase (ITK) as an off-target effect but BGB-3111 does not inhibit ITK. ibrutinib 73-82 IL2 inducible T cell kinase Homo sapiens 96-119 34508613-5 2021 BGB-3111 provides better safety than another BTK inhibitor, ibrutinib as ibrutinib inhibits the inducible T-cell kinase (ITK) as an off-target effect but BGB-3111 does not inhibit ITK. ibrutinib 73-82 IL2 inducible T cell kinase Homo sapiens 121-124 34065833-5 2021 Ibrutinib, through ITK-driven Th1 polarization of cell-mediated immune response, is known to produce an immunological rebalancing in CLL, which stands as a fascinating rationale for its use to treat autoimmunity. ibrutinib 0-9 IL2 inducible T cell kinase Homo sapiens 19-22 34987640-9 2022 Further, to reactivate functionally indolent TILs, we reprogrammed ex vivo TILs with Ibrutinib plus Rapamycin to block interleukin-2-inducible kinase (ITK) and mTOR pathways, respectively. ibrutinib 85-94 IL2 inducible T cell kinase Homo sapiens 119-149 34987640-9 2022 Further, to reactivate functionally indolent TILs, we reprogrammed ex vivo TILs with Ibrutinib plus Rapamycin to block interleukin-2-inducible kinase (ITK) and mTOR pathways, respectively. ibrutinib 85-94 IL2 inducible T cell kinase Homo sapiens 151-154